Abstract
In the May, 2011, issue of The Lancet Oncology, Frédéric Peyrade and colleagues reported the efficacy and safety of a decreased dose of CHOP (doxorubicin, cyclophosphamide, vincristine, and prednisone) chemotherapy with a conventional dose of rituximab for patients older than 80 years of age with diffuse large B-cell lymphoma (DLBCL).1 The results of their investigation—done by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)—were uniformly excellent and had a vital effect on the management of very elderly patients with DLBCL.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
